Go Pro
→ Your book attached (From Profits Run) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
$0.06
-14.2%		$0.06
$0.03
▼
$0.11
$686K1.5222,213 shs10,568 shs
Jupiter Neurosciences, Inc. stock logo
JUNS
Jupiter Neurosciences
$0.08
-2.5%		$0.19
$0.07
▼
$1.84
$2.79M1.9822.35 million shs1.43 million shs
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
$0.39
-1.3%		$2.27
$0.16
▼
$17.38
$2.77M1.831.83 million shs2.16 million shs
Vaccinex, Inc. stock logo
VCNX
Vaccinex
$1.12
$1.06
$0.31
▼
$1.50
$2.91M1.13,233 shs4 shs
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
-14.16%+30.43%-24.05%+5.26%+49.25%
Jupiter Neurosciences, Inc. stock logo
JUNS
Jupiter Neurosciences
-2.47%-22.97%-65.20%-77.43%-94.56%
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
-1.28%-62.25%-83.41%-84.41%-97.65%
Vaccinex, Inc. stock logo
VCNX
Vaccinex
0.00%-5.08%0.00%+10.89%+49.33%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
$0.06
-14.2%		$0.06
$0.03
▼
$0.11
$686K1.5222,213 shs10,568 shs
Jupiter Neurosciences, Inc. stock logo
JUNS
Jupiter Neurosciences
$0.08
-2.5%		$0.19
$0.07
▼
$1.84
$2.79M1.9822.35 million shs1.43 million shs
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
$0.39
-1.3%		$2.27
$0.16
▼
$17.38
$2.77M1.831.83 million shs2.16 million shs
Vaccinex, Inc. stock logo
VCNX
Vaccinex
$1.12
$1.06
$0.31
▼
$1.50
$2.91M1.13,233 shs4 shs
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
-14.16%+30.43%-24.05%+5.26%+49.25%
Jupiter Neurosciences, Inc. stock logo
JUNS
Jupiter Neurosciences
-2.47%-22.97%-65.20%-77.43%-94.56%
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
-1.28%-62.25%-83.41%-84.41%-97.65%
Vaccinex, Inc. stock logo
VCNX
Vaccinex
0.00%-5.08%0.00%+10.89%+49.33%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
0.00
N/AN/AN/A
Jupiter Neurosciences, Inc. stock logo
JUNS
Jupiter Neurosciences
1.00
SellN/AN/A
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
2.33
Hold$22.005,614.29% Upside
Vaccinex, Inc. stock logo
VCNX
Vaccinex
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest HEPA, VCNX, JUNS, and MBRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/17/2026
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
6/24/2026
Jupiter Neurosciences, Inc. stock logo
JUNS
Jupiter Neurosciences
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
(Data available from 8/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
N/AN/AN/AN/A$1.29 per shareN/A
Jupiter Neurosciences, Inc. stock logo
JUNS
Jupiter Neurosciences
$20K136.23N/AN/A($0.05) per share-1.50
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
N/AN/AN/AN/A$4.69 per shareN/A
Vaccinex, Inc. stock logo
VCNX
Vaccinex
$388K7.51N/AN/A($2.59) per share-0.43
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
-$48.93M-$72.15N/AN/AN/AN/A-812.56%-207.31%9/2/2026 (Estimated)
Jupiter Neurosciences, Inc. stock logo
JUNS
Jupiter Neurosciences
-$8.65M-$0.27N/AN/AN/AN/A-1,314.62%-228.63%9/2/2026 (Estimated)
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
-$33.56M-$17.98N/AN/AN/AN/AN/A-70.93%8/11/2026 (Estimated)
Vaccinex, Inc. stock logo
VCNX
Vaccinex
-$20.25M-$48.27N/AN/AN/AN/AN/A-383.58%8/10/2026 (Estimated)

Latest HEPA, VCNX, JUNS, and MBRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
9/2/2026Q2 2026
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
-$200.00N/AN/AN/AN/AN/A
9/2/2026N/A
Jupiter Neurosciences, Inc. stock logo
JUNS
Jupiter Neurosciences
-$0.05N/AN/AN/A$0.40 millionN/A
8/11/2026Q2 2026
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
-$1.54N/AN/AN/AN/AN/A
8/10/2026N/A
Vaccinex, Inc. stock logo
VCNX
Vaccinex
-$73.0380N/AN/AN/A$0.63 millionN/A
5/14/2026Q1 2026
Jupiter Neurosciences, Inc. stock logo
JUNS
Jupiter Neurosciences
-$0.05-$0.06-$0.01-$0.06$0.23 million$0.02 million
5/14/2026Q1 2026
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
-$2.3333-$3.54-$1.2067-$3.54N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
N/AN/AN/AN/AN/A
Jupiter Neurosciences, Inc. stock logo
JUNS
Jupiter Neurosciences
N/AN/AN/AN/AN/A
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
N/AN/AN/AN/AN/A
Vaccinex, Inc. stock logo
VCNX
Vaccinex
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
N/A
1.30
1.30
Jupiter Neurosciences, Inc. stock logo
JUNS
Jupiter Neurosciences
N/A
0.51
0.48
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
N/A
1.38
1.38
Vaccinex, Inc. stock logo
VCNX
Vaccinex
N/A
0.77
0.77

Institutional Ownership

CompanyInstitutional Ownership
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
17.24%
Jupiter Neurosciences, Inc. stock logo
JUNS
Jupiter Neurosciences
N/A
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
15.52%
Vaccinex, Inc. stock logo
VCNX
Vaccinex
50.11%

Insider Ownership

CompanyInsider Ownership
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
0.06%
Jupiter Neurosciences, Inc. stock logo
JUNS
Jupiter Neurosciences
38.60%
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
1.10%
Vaccinex, Inc. stock logo
VCNX
Vaccinex
51.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
2011.44 million6.63 millionNo Data
Jupiter Neurosciences, Inc. stock logo
JUNS
Jupiter Neurosciences
536.28 million22.28 millionNot Optionable
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
207.10 million7.02 millionNot Optionable
Vaccinex, Inc. stock logo
VCNX
Vaccinex
402.60 million1.26 millionNo Data

Recent News About These Companies

Vaccinex to Report New Biomarker Data and Plans for Phase 2B Clinical Trial of Pepinemab in AD at the Alzheimer's Association International Conference in London on July 13, 2026
July 8, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/08/3324070/34858/en/vaccinex-to-report-new-biomarker-data-and-plans-for-phase-2b-clinical-trial-of-pepinemab-in-ad-at-the-alzheimer-s-association-international-conference-in-london-on-july-13-2026.html
Vaccinex, Inc. Reports Financial Results for Year Ended December 31, 2025
April 29, 2026  |  quiverquant.comQ
Vaccinex Reports 2025 Annual Financial Results
April 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/30/3284388/34858/en/vaccinex-reports-2025-annual-financial-results.html
Vaccinex Inc.
April 10, 2026  |  barrons.comhttps://www.barrons.com/market-data/stocks/vcnx/company-people
Vaccinex announces $60M revenue sharing agreement with PDV
December 23, 2025  |  msn.comhttps://www.msn.com/en-us/money/other/vaccinex-announces-60m-revenue-sharing-agreement-with-pdv/ar-AA1SUmDZ
Vaccinex, Inc. Announces $60 million Agreement to Finance a Phase 2b clinical trial of pepinemab to treat Alzheimer’s Disease
December 23, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/vaccinex-inc-announces-60-million-agreement-to-finance-a-phase-2b-clinical-trial-of-pepinemab-to-treat-alzheimer-s-disease-1035667359
Vaccinex, Inc. Engages in $60 Million Revenue Sharing Agreement with Pepinemab Development Venture to Advance Alzheimer’s Treatment
December 23, 2025  |  quiverquant.comQ
Vaccinex presents promising cancer treatment data at ASCO
May 29, 2025  |  uk.investing.comhttps://uk.investing.com/news/company-news/vaccinex-presents-promising-cancer-treatment-data-at-asco-93CH-4104876
Vaccinex, Inc. to Present New Data on Pepinemab's Role in Enhancing Immune Responses in Head and Neck Cancer at ASCO 2025
May 29, 2025  |  nasdaq.comhttps://www.nasdaq.com/articles/vaccinex-inc-present-new-data-pepinemabs-role-enhancing-immune-responses-head-and-neck
Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting
May 27, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/05/27/3088645/34858/en/vaccinex-to-report-promising-new-clinical-results-of-neoadjuvant-treatment-with-pepinemab-to-enhance-immunotherapy-in-patients-with-head-and-neck-cancer-at-asco-annual-meeting.html
AbTherx, Inc: AbTherx, Single Cell Technology, and Vaccinex Announce Collaboration to Tackle Challenging Antibody Drug Targets
May 13, 2025  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2025-05/65384714-abtherx-inc-abtherx-single-cell-technology-and-vaccinex-announce-collaboration-to-tackle-challenging-antibody-drug-targets-200.htm
AbTherx, Single Cell Technology, and Vaccinex Announce Collaboration to Tackle Challenging Antibody Drug Targets
May 13, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/abtherx-single-cell-technology-vaccinex-100000437.html
Vaccinex to report new clinical data on pepinemab in enhancing immunotherapy
April 22, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/vaccinex-to-report-new-clinical-data-on-pepinemab-in-enhancing-immunotherapy-1034603197
Vaccinex, Inc. Announces Promising Data on Pepinemab as Neoadjuvant Immunotherapy in Metastatic Melanoma and Head and Neck Cancer at AACR 2025
April 21, 2025  |  quiverquant.comQ
Vaccinex to Report Promising New Clinical Data Revealing Pepinemab's Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR)
April 21, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/04/21/3064665/34858/en/vaccinex-to-report-promising-new-clinical-data-revealing-pepinemab-s-unique-mechanism-to-enhance-immunotherapy-at-annual-meeting-of-american-association-for-cancer-research-aacr.html
Vaccinex director resigns, no disagreement cited
March 21, 2025  |  investing.comhttps://www.investing.com/news/sec-filings/vaccinex-director-resigns-no-disagreement-cited-93CH-3937856
Vaccinex plans Nasdaq exit as Alzheimer market pressure grows
March 10, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/vaccinex-plans-nasdaq-exit-alzheimer-211545558.html
Vaccinex, Inc.: Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market
March 8, 2025  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2025-03/64767350-vaccinex-inc-vaccinex-plans-to-delist-its-common-stock-from-the-nasdaq-stock-market-399.htm
Vaccinex to delist common stock from Nasdaq
March 7, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/vaccinex-to-delist-common-stock-from-nasdaq-1034455385
Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market
March 7, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/03/07/3039274/34858/en/vaccinex-plans-to-delist-its-common-stock-from-the-nasdaq-stock-market.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Hepion Pharmaceuticals stock logo

Hepion Pharmaceuticals NASDAQ:HEPA

$0.06 -0.01 (-14.16%)
As of 08/6/2026 01:31 PM Eastern

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.

Jupiter Neurosciences stock logo

Jupiter Neurosciences NASDAQ:JUNS

$0.08 0.00 (-2.47%)
Closing price 08/6/2026 04:00 PM Eastern
Extended Trading
$0.07 0.00 (-0.67%)
As of 08/6/2026 06:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease. In addition, it is developing JNS109 for amyotrophic lateral sclerosis; JNS110 for traumatic brain injury/concussion; and JNS120 for covid-19 treatment. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. The company was founded in 2016 and is headquartered in Jupiter, Florida.

Moleculin Biotech stock logo

Moleculin Biotech NASDAQ:MBRX

$0.38 -0.01 (-1.28%)
Closing price 08/6/2026 04:00 PM Eastern
Extended Trading
$0.39 +0.01 (+1.30%)
As of 06:51 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.

Vaccinex stock logo

Vaccinex NASDAQ:VCNX

$1.12 0.00 (0.00%)
As of 08/5/2026

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. It is developing Pepinemab, which is in phase 2 study for treatment of Alzheimer's disease and has completed phase 2 study for treatment of Huntington's disease; Pepinemab in combination with Pembrolizumab in phase 2 study for head and neck cancer, Avelumab in phase 2 study for pancreatic cancer, and completed phase 2 study with Avelumab for non-small cell lung cancer; and Pepinemab in combination with Nivolumab completed phase 2 study for melanoma, and trastuzumab and DC vaccine in phase 2 study for breast cancer. The company has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. It has collaborations with Merck Sharp & Dohme; Ares Trading S.A.; The Children's Hospital of Philadelphia; Emory University; Huntington Study Group; H. Lee Moffitt Cancer Center and Research Institute, Inc; Catalent Pharma Solutions, LLC; Surface Oncology, Inc.; and Pharmaceutical and Biotech Co. The company was incorporated in 2001 and is headquartered in Rochester, New York.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas